Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Trio of cancer start-ups launches

by Lisa M. Jarvis
March 14, 2016 | A version of this story appeared in Volume 94, Issue 11

Three cancer-focused firms have launched. Tizona Therapeutics is emerging from stealth mode with more than $70 million to support the development of immunotherapies for cancer and autoimmune diseases. Tizona expects to put its first drug candidate, an antibody against CCR4, a protein expressed on certain T cells, into human studies in 2017. Separately, Horizon Discovery and Centauri Therapeutics have formed the immuno-oncology firm Avvinity Therapeutics. Horizon will contribute gene-editing, immunology, and drug discovery expertise and invest up to $7.5 million in Avvinity. Lastly, Capella BioScience launched with $15.5 million in funding to develop antibodies against cancer and immunology targets.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.